# US 2019/0315872 A1 · Anti-c-met antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315872 A1
- Document ID: US20190315872A1
- Status: Published application
- Kind: A1
- Application number: 16/075,304
- Filed: 2017-02-06
- Published: 2019-10-17
- Earliest claimed: 2016-02-05
- Assignees: ViroMed Co., Ltd.
- Applicants: Viromed Co., Ltd.
- Inventors: Seung Shin YU; Jae-Gyun JEONG; Dongsik KIM; Juwon SHIM
- Web page: https://patentgrep.com/patent/US20190315872A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/75: Agonist effect on antigen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.

## Claims

### Claim 1

A method for treating a disease selected from the group consisting of ischemic disorder, stroke, kidney injury or disease, retinal neovascularization disorder, neurological disorder or disease, and wound healing, the method comprising administering to a subject in need thereof a therapeutically effective amount of a polypeptide or a pharmaceutical composition comprising the polypeptide, wherein the polypeptide comprises an immunoglobulin heavy chain variable domain which comprises a CDR1 of SEQ ID NO:5, a CDR2 of SEQ ID NO:6, a CDR3 of SEQ ID NO:7 and a light chain variable domain which comprises a CDR1 of SEQ ID NO:8, a CDR2 of SEQ ID NO:9 and a CDR3 of SEQ ID NO:10.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method according to claim 1, wherein the ischemic disorder is selected from the group consisting of ischemia of brain tissue, heart tissue, kidney tissue, or intestinal tissue.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method according to claim 1, wherein the stroke is an embolic stroke or a thrombotic stroke.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein the kidney injury or disease is a fibrotic condition.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the kidney injury or disease is selected from the group consisting of renal fibrosis, chronic kidney fibrosis, chronic nephropathy associated with diabetes, lupus, scleroderma of the kidney, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathyrenal fibrosis associated with human chronic kidney disease (C D), chronic progressive nephropathy (CPN), tubulointerstitial fibrosis, ureteral obstruction, chronic uremia, chronic interstitial nephritis, radiation nephropathy, glomerulosclerosis, progressive glomerulonephrosis (PGN), endothelial/thrombotic microangiopathy injury, HIV-associated nephropathy, and a fibrosis associated with exposure to a toxin, an irritant, or a chemotherapeutic agent.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method according to claim 1, wherein the retinal neovascularization disorder is caused by a member selected from the group consisting of macular degeneration, histoplasmosis, pathological myopia, angioid streaks, anterior ischemic optic neuropathy, bacterial endocarditis, Best's disease, birdshot retinochoroidopathy, choroidal hemangioma, choroidal nevi, choroidal nonperfusion, choroidal osteomas, choroidal rupture, choroideremia, chronic retinal detachment, coloboma of the retina, Drusen, endogenous Candida endophthalmitis, extrapapillary hamartomas of the retinal pigmented epithelium, fundus flavimaculatus, idiopathic, macular hole, malignant melanoma, membranoproliferative glomerulonephritis (type II), metallic intraocular foreign body, morning glory disc syndrome, multiple evanescent white-dot syndrome (MEWDS), neovascularization at ora Serrata, operating microscope burn, optic nerve head pits, photocoagulation, punctuate inner choroidopathy, rubella, sarcoidosis, serpiginous or geographic choroiditis, subretinal fluid drainage, tilted disc syndrome, Taxoplasma retinochoroiditis, tuberculosis, Vogt-Koyanagi-Harada syndrome, diabetic retinopathy, non-diabetic retinopathy, branch vein occlusion, central retinal vein occlusion, retinopathy in premature infants, rubeosis iridis, neovascular glaucoma, periofoveal telangiectasis, sickle cell retinopathy, Eale's disease, retinal vasculitis, Von Hippel Linau disease, radiation retinopathy, retinal cryoinjury, retinitis pigmentosa, retinochoroidal coloboma, corneal neovascularization due to herpes simplex keratitis, corneal ulcers, keratoplasty, pterigyia, and trauma.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the retinal neovascularization disorder is choroidal neovascularization.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method according to claim 1, wherein the neurological disorder or disease is selected from the group consisting of traumatic brain injury, stroke, cerebral aneurism, spinal cord injury, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, diffuse cerebral cortical atrophy, Lewy-body dementia, Pick disease, mesolimbocortical dementia, thalamic degeneration, Huntington chorea, cortical-striatal-spinal degeneration, cortical-basal ganglionic degeneration, cerebrocerebellar degeneration, familial dementia with spastic paraparesis, polyglucosan body disease, Shy-Drager syndrome, olivopontocerebellar atrophy, progressive supranuclear palsy, dystonia musculorum deformans, Hallervorden-Spatz disease, eige syndrome, familial tremors, Gilles de la Tourette syndrome, acanthocytic chorea,
Friedreich ataxia, Holmes familial cortical cerebellar atrophy, Gerstmann-Straussler-Scheinker disease, progressive spinal muscular atrophy, progressive balbar palsy, primary lateral sclerosis, hereditary muscular atrophy, spastic paraplegia, peroneal muscular atrophy, hypertrophic interstitial polyneuropathy, heredopathia atactica polyneuritiformis, optic neuropathy, ophthalmoplegia, and retina or optic nerve damage.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method according to claim 1, wherein the wound is a mechanical, chemical, bacterial, or thermal wound.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the wound is selected from the group consisting of an incision, a laceration, an abrasion, a puncture wound, a penetration wound, and a gunshot wound.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the wound is a skin wound.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the heavy chain variable domain comprises SEQ ID NO: I and the light chain variable domain comprises SEQ ID NO:2.

### Claim 19 (depends on 1)

The method according to claim 1 wherein the polypeptide is an antibody or fragment thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the antibody or fragment thereof is a chimeric antibody, a humanized antibody, or a human antibody.

### Claim 21 (depends on 1)

The method according to claim 1, wherein the polypeptide comprises a scFv.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the heavy chain variable domain comprises SEQ ID NO:1 and the light chain variable domain comprises SEQ ID NO:2.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the scFv comprises SEQ ID NO:3.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the administering is intravenous, intravitreal, intrathecal, parenteral, subcutaneous, topical, transdermal or by infusion.

### Claim 25 (depends on 1)

The method according to claim 1, wherein the subject is not suffering from a cancer.

### Claim at position 26

26-29. (canceled)
